Cochrane · systematic review · CD011772
Rufinamide add‐on therapy for drug‐resistant epilepsy
Panebianco, M, Prabhakar, H, Marson, AG · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 20%Moderate 8 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRufinamide versus placebo for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency ‐ ITT analysis Rufinamide vs placebo | RR 1.79 [1.44, 2.22] | 6 studies · 1759 participants | Moderate Downgraded: risk of bias |
Seizure freedom Rufinamide vs placebo | RR 1.32 [0.36, 4.86] | 1 study · 73 participants | Moderate Downgraded: risk of bias |
Treatment withdrawal Rufinamide vs placebo | RR 1.83 [1.45, 2.31] | 6 studies · 1759 participants | Moderate Downgraded: risk of bias |
Adverse effects: dizziness Rufinamide vs placebo | RR 2.52 [1.9, 3.34] | 3 studies · 1295 participants | Moderate Downgraded: risk of bias |
Adverse effects: fatigue Rufinamide vs placebo | RR 1.46 [1.08, 1.97] | 3 studies · 1295 participants | Moderate Downgraded: risk of bias |
Adverse effects: headache Rufinamide vs placebo | RR 1.36 [1.08, 1.69] | 3 studies · 1228 participants | Moderate Downgraded: risk of bias |
Adverse effects: somnolence Rufinamide vs placebo | RR 1.94 [1.44, 2.61] | 6 studies · 1759 participants | Moderate Downgraded: risk of bias |
Adverse effects: nausea Rufinamide vs placebo | RR 1.87 [1.33, 2.64] | 3 studies · 1295 participants | Moderate Downgraded: risk of bias |
Adverse effects: vomiting Rufinamide vs placebo | RR 2.95 [1.8, 4.82] | 4 studies · 777 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: diplopia Rufinamide vs placebo | RR 4.6 [2.53, 8.38] | 3 studies · 1295 participants | Low Downgraded: risk of bias, imprecision |
Rufinamide versus placebo for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency ‐ ITT analysis Rufinamide vs placebo | RR 1.79 [1.44, 2.22] | 6 studies · 1759 participants | Moderate Downgraded: risk of bias, imprecision |
Treatment withdrawal Rufinamide vs placebo | RR 1.83 [1.45, 2.31] | 6 studies · 1759 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse effects: dizziness Rufinamide vs placebo | RR 2.52 [1.9, 3.34] | 3 studies · 1295 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse effects: fatigue Rufinamide vs placebo | RR 1.46 [1.08, 1.97] | 3 studies · 1295 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse effects: headache Rufinamide vs placebo | RR 1.36 [1.08, 1.69] | 3 studies · 1228 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse effects: somnolence Rufinamide vs placebo | RR 1.94 [1.44, 2.61] | 6 studies · 1759 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse effects: nausea Rufinamide vs placebo | RR 1.87 [1.33, 2.64] | 3 studies · 1295 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse effects: vomiting Rufinamide vs placebo | RR 2.95 [1.8, 4.82] | 4 studies · 777 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: diplopia Rufinamide vs placebo | RR 4.6 [2.53, 8.38] | 3 studies · 1295 participants | Low Downgraded: risk of bias, imprecision |